PeterO'DwyerMD

PubMed

• 19 citations
  Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of NUT carcinoma and other cancers: results of a phase I/II open-label, ...
  Sophie Cousin, Jean-Yves Blay, Irene Braña Garcia, Johann S. de Bono, Christophe Le Tourneau, Victor Moreno, Jose Manuel Trigo, Christine L. Hann, Arun Azad, Seock-Ah ...> ;International Journal of Cancer. 2021 Nov 1
• 1 citations
  THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma.
  Phyllis A. Gimotty, Jacob Till, Shirsa Udgata, Naomi Takenaka, Stephanie S. Yee, Michael J. LaRiviere, Mark H. O'Hara, Kim A. Reiss, Peter O'Dwyer, Bryson W. Katona, D...> ;Oncotarget. 2021 Oct 26
• 5 citations
  Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: ...
  Komal Jhaveri, X. V. Wang, Vicky Makker, Shiuh-Wen Luoh, Edith P. Mitchell, James A. Zwiebel, Elad Sharon, Robert Gray, Shuli Li, Lisa M. McShane, Larry Rubinstein, Da...> ;Annals of Oncology. 2021 Jun 4
• 19 citations
  Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors.
  James M. Cleary, Victoria Wang, Rebecca S. Heist, E. Scott Kopetz, Edith P. Mitchell, James A. Zwiebel, Kevin S. Kapner, Helen X. Chen, Shuli Li, Robert Gray, Lisa M. ...> ;Clinical Cancer Research. 2021 Jun 1
• 39 citations
  Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
  Kevin Kalinsky, Fangxin Hong, Carolyn K. McCourt, Jasgit C. Sachdev, Edith P. Mitchell, James A. Zwiebel, L. Austin Doyle, Lisa M. McShane, Shuli Li, Robert Gray, Larr...> ;JAMA Oncology. 2021 Feb 1
• 9 citations
  What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report
  Monica M. Bertagnolli, Charles D. Blanke, Walter J. Curran, Douglas S. Hawkins, Robert S. Mannel, Peter J. O'Dwyer, Mitchell D. Schnall, Norman Wolmark> ;Cancer. 2020 Dec 1
• 20 citations
  Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric Cancer.
  Thomas B. Karasic, Mark H. O'Hara, Ursina R. Teitelbaum, Nevena Damjanov, Bruce J. Giantonio, Tracy S. d'Entremont, Maryann Gallagher, Paul J. Zhang, Peter J. O'Dwyer> ;The Oncologist. 2020 Dec 1
• 132 citations
  Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
  Keith T. Flaherty, Robert Gray, Alice P. Chen, Shuli Li, Lisa M. McShane, David Patton, Stanley R. Hamilton, P. Mickey Williams, A. John Iafrate, Jeffrey Sklar, Edith ...> ;Journal of Clinical Oncology. 2020 Oct 13
• 5 citations
  Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial.
  Alice P. Chen, Keith T. Flaherty, Peter J. O'Dwyer, Bruce J. Giantonio, Donna M. Marinucci, Ju-Whei Lee, Elda Railey, Mary Lou Smith, Carol B. White, Barbara A. Conley> ;JCO Precision Oncology. 2020 Oct 5
• 5 citations
  Comparing the clinical impact of pancreatic cyst surveillance programs: A trial of the ECOG-ACRIN cancer research group (EA2185)
  David S. Weinberg, Constantine Gatsonis, Herbert J. Zeh, Ruth C. Carlos, Peter J. O'Dwyer, Ea Team> ;Contemporary Clinical Trials. 2020 Sep 10
• 117 citations
  Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.
  April K.S. Salama, Shuli Li, Erin Macrae, Jong-In Park, Edith P. Mitchell, James A. Zwiebel, Helen X. Chen, Robert Gray, Lisa M. McShane, Larry Rubinstein, David Patto...> ;Journal of Clinical Oncology. 2020 Aug 6
• 13 citations
  Early treatment-related neutropenia predicts response to palbociclib.
  Nicholas P. McAndrew, Mark A. Dickson, Amy S. Clark, Andrea B. Troxel, Mark H. O'Hara, Christopher Colameco, Maryann Gallager, Kristi Gramlich, Kelly Zafman, David J. ...> ;British Journal of Cancer. 2020 Jul 9
• 64 citations
  Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
  Zev A. Wainberg, Howard S. Hochster, Edward J. Kim, Ben George, Aparna Kaylan, E. Gabriela Chiorean, David M. Waterhouse, Martin Guiterrez, Aparna Raj Parikh, Rishi Ja...> ;Clinical Cancer Research. 2020 Sep 15
• 29 citations
  BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal ...
  Gary Middleton, Yiqun Yang, Catarina D. Campbell, Thierry André, Chloe E. Atreya, Jan H.M. Schellens, Takayuki Yoshino, Johanna C. Bendell, Antoine Hollebecque, Autumn...> ;Clinical Cancer Research. 2020 Feb 11
• 76 citations
  Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
  Young Kwang Chae, Fangxin Hong, Christos Vaklavas, Heather H. Cheng, Peter S. Hammerman, Edith P. Mitchell, James A. Zwiebel, S. Percy Ivy, Robert Gray, Shuli Li, Lisa...> ;Journal of Clinical Oncology. 2020 May 28
• 11 citations
  Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for ...
  A. Bapsi Chakravarthy, Fengmin Zhao, Neal J. Meropol, Patrick J. Flynn, Lynne I. Wagner, Jeff A. Sloan, Robert B. Diasio, Edith P. Mitchell, Paul J. Catalano, Bruce J....> ;The Oncologist. 2020 May 1
• 35 citations
  Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
  Douglas B. Johnson, Fengmin Zhao, Marcus Smith Noel, Gregory J. Riely, Edith P. Mitchell, John J. Wright, Helen X. Chen, Robert Gray, Shuli Li, Lisa M. McShane, Larry ...> ;Clinical Cancer Research. 2020 Apr 15
• 103 citations
  Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
  Sarina Anne Piha-Paul, Christine L. Hann, Christopher A. French, Sophie Cousin, Irene Brana, P. A. Cassier, Victor Moreno, Johann S. de Bono, Sara Duckworth Harward, G...> ;JNCI Cancer Spectrum. 2020 Apr 1
• 95 citations
  Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma.
  Ana De Jesus-Acosta, Elizabeth A. Sugar, Peter J. O'Dwyer, Ramesh K. Ramanathan, Daniel D. Von Hoff, Zeshaan A. Rasheed, Lei Zheng, Asma Begum, Robert A. Anders, Anirb...> ;British Journal of Cancer. 2020 Feb 18
• 85 citations
  Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer
  Brian C. Baumann, Nandita Mitra, Joanna Harton, Ying Xiao, Andrzej P. Wojcieszynski, Peter Gabriel, Haoyu Zhong, H. Geng, Abigail Doucette, Jenny J. Wei, Peter J. O'Dw...> ;JAMA Oncology. 2020 Feb 1
• 107 citations
  Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
  Max M. Wattenberg, Daniella Asch, Shun Yu, Peter J. O'Dwyer, Susan M. Domchek, Katherine L. Nathanson, Mark A. Rosen, Gregory L. Beatty, Evan S. Siegelman, Kim A. Reiss> ;British Journal of Cancer. 2020 Feb 1
• Erratum: Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma (Proceedings of the National Academy of Scienc...
  Rebecca L. Porter, Neelima K.C. Magnus, Vishal Thapar, Robert Morris, Annamaria Szabolcs, Azfar Neyaz, Anupriya S. Kulkarni, Eric Tai, Abhijit Chougule, Alessandra Hil...> ;Proceedings of the National Academy of Sciences of the United States of America. 2020 Jan 21
• 84 citations
  Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study
  Nilofer S. Azad, Robert Gray, Michael J. Overman, Jonathan D. Schoenfeld, Edith P. Mitchell, James A. Zwiebel, Elad Sharon, Howard Streicher, Shuli Li, Lisa M. McShane...> ;Journal of Clinical Oncology. 2020 Jan 20
• 61 citations
  Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma.
  Rebecca L. Porter, Neelima K.C. Magnus, Vishal Thapar, Robert Morris, Annamaria Szabolcs, Azfar Neyaz, Anupriya S. Kulkarni, Eric Tai, Abhijit Chougule, Alessandra Hil...> ;Proceedings of the National Academy of Sciences of the United States of America. 2019 Dec 26
• 11 citations
  Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small...
  Jonathan W. Goldman, David M. Waterhouse, Ben George, Peter J. O'Dwyer, Rafia Bhore, Sibabrata Banerjee, Larry Lyons, Chrystal U. Louis, Teng Jin Ong, Karen Kelly> ;Frontiers in Oncology. 2019 Nov 26
• Join now to see all

Journal Articles

• Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy  
  Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimoseg..., Cell, 2014
• A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.  
  Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer PJ., Clin Cancer Res, 2013
• Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.  
  Tabernero J, Garcia-Carbonero R, Cassidy J, Sobrero A, Van Cutsem E, Köhne CH, Tejpar S, Gladkov O, Davidenko I, Salazar R, Vladimirova L, Cheporov S, Burdaeva O, Rive..., Clin Cancer Res, 2013
• Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy.  
  Selvakumaran M, Amaravadi RK, Vasilevskaya IA, O'Dwyer PJ, Clin Cancer Res, 2013
• Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.  
  Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA 3rd, Mess..., Lancet Oncology, 2012
• Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).  
  Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, Courtney R, O'Dwyer PJ., Br J Cancer, 2012
• CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.  
  Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH., Science, 2011
• Inhibition of mutated, activated BRAF in metastatic melanoma.  
  Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB, New Engl J Med, 2010
• Join now to see all

Lectures

• Basket Trials in Colorectal Cancer 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018